A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2017
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms SR-GS
- 15 Jan 2017 Status changed from recruiting to discontinued due to slow recruitment.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Sep 2013 New trial record